Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China · Delayed Price · Currency is CNY

44.41

+0.65 (1.49%)

Sep 14, 2026, 3:00 PM CST

Hangzhou Alltest Biotech Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	867.64	905.34	866.58	754.7	3,389	1,873
Revenue Growth	-3.59%	4.47%	14.82%	-77.73%	80.88%	64.98%
Gross Profit	422.26	456.99	473.77	374.04	1,826	1,030
Operating Income	122.46	176.14	240.6	99.01	1,354	837.67
Net Income	139.02	220.19	302.47	180.58	1,185	765.69
Earnings Per Share	1.75	2.78	3.82	2.28	14.95	10.24
EPS Growth	-55.47%	-27.22%	67.54%	-84.75%	46.05%	-9.93%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	63.01
Overseas	836.44
Total	899.45

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	2,124	2,392	2,578	2,789	3,815	2,960
Total Debt	7.03	7.41	4.1	23.91	21.77	37.36
Net Cash (Debt)	2,117	2,385	2,574	2,765	3,793	2,922
Net Cash Growth	-13.88%	-7.34%	-6.92%	-27.10%	29.80%	317.07%
Net Cash Per Share	26.66	30.11	32.50	34.91	47.86	39.07

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	198.12	206.59	329.52	24.76	1,361	923.87
Capital Expenditures	-141	-219.1	-220.65	-533.49	-270.24	-140.12
Free Cash Flow	57.13	-12.5	108.87	-508.73	1,090	783.75
Free Cash Flow Growth	-21.84%	-	-	-	39.13%	33.84%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	48.67%	50.48%	54.67%	49.56%	53.87%	54.96%
Operating Margin	14.11%	19.46%	27.76%	13.12%	39.97%	44.71%
Pretax Margin	17.64%	27.74%	40.12%	26.16%	40.77%	47.80%
Profit Margin	16.02%	24.32%	34.90%	23.93%	34.97%	40.87%
FCF Margin	6.58%	-1.38%	12.56%	-67.41%	32.18%	41.84%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	2.000	2.000	3.000	1.500	6.757	2.703
Dividend Per Share Growth	-33.33%	-33.33%	100.00%	-77.80%	150.00%	99.99%
Dividend Yield	4.37%	3.20%	5.02%	2.44%	11.84%	4.14%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	25.36	22.72	16.23	29.69	4.66	8.66
P/FCF Ratio	60.15	-	45.10	-	5.06	8.46
PS Ratio	3.96	5.53	5.67	7.10	1.63	3.54